# 2026-23351: FDA Moves To Settle NAC’s Long, Strange Supplement Status

2026-23351, Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition, is a Federal Register proposed rule from Health and Human Services Department, Food and Drug Administration published 2026-11-17, effective Any final rule resulting from this rulemaking would become effective immediately upon publication of the final rule.; deemed significant under Executive Order 12866; PRIA reads it as touching household money (as of 2026-11-17).

- Canonical: https://policyrisk.com/federal-register/2026-23351
- As of: 2026-11-17
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-23351
- Title: Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition
- Type: Proposed Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 73717
- Published: 2026-11-17
- Effective: Any final rule resulting from this rulemaking would become effective immediately upon publication of the final rule.
- Comments close: 2027-01-19
- Significant: yes (FR_METADATA)
- Touches household money: yes
- Regulation identifier numbers: 0910-AI91
- Last updated: 2026-11-17

## In one line

FDA Moves To Settle NAC’s Long, Strange Supplement Status

## Summary

The FDA wants to officially say that N-acetyl-L-cysteine (NAC) can be sold as a dietary supplement. This means companies can legally put NAC in their products without breaking the rules, as long as they follow other laws. People and businesses making or selling supplements with NAC should share their thoughts by January 19, 2027.

## Abstract

The Food and Drug Administration (FDA or we) is proposing to issue a regulation finding that N-acetyl-L-cysteine (NAC) is not excluded from the dietary supplement definition in the Federal Food, Drug, and Cosmetic Act (FD&C Act). This action, if finalized, would allow products containing NAC to be lawfully marketed as dietary supplements, provided that such products are not otherwise in violation of the FD&C Act. We also propose to provide that the addition of NAC to a dietary supplement is not a prohibited act under section 301(ll) of the FD&C Act.

## Effects PRIA read

- NAC can be sold as dietary supplements: benefit, medium. If finalized, FDA would place N-acetyl-L-cysteine (NAC) on a regulation (proposed §190.1(a)) confirming NAC is not excluded from the statutory dietary supplement definition and that adding NAC to a dietary supplement is not a prohibited act under section 301(ll) of the FD&C Act. That means products…
- Small compliance reading costs for industry: cost, low. FDA estimates the rule's primary annualized industry compliance costs (for reading and understanding the rule) are about $99 per year at a 3% discount rate and $121 per year at a 7% discount rate, with a present value of total costs of approximately $848 when annualized over 10 years. FDA states th…
- FDA found minimal safety concerns for oral NAC: benefit, low. FDA's systematic review identified 41 high-confidence studies of orally administered NAC and concluded a "minimal" Level of Concern for adverse events. Studies included doses up to 9,000 mg per day and durations up to 3 years; commonly labeled dietary supplement servings overlap with study doses (e…
- NAC supplements must meet dietary supplement rules: cost, low. If NAC is allowed as a dietary supplement, NAC-containing products would be subject to all requirements that apply to dietary supplements under the FD&C Act and FDA implementing regulations (for example, current Good Manufacturing Practice requirements at 21 CFR part 111). FDA states any adulterate…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-23351 on federalregister.gov](https://www.federalregister.gov/documents/2026/11/17/2026-23351/rulemaking-to-provide-that-n-acetyl-l-cysteine-is-not-excluded-from-the-dietary-supplement)
- [2026-23351 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-11-17/pdf/2026-23351.pdf)

## Related
- [Previous: 2026-23342, Advisory Committee on Reactor Safeguards Functions](https://policyrisk.com/federal-register/2026-23342)
- [Next: 2026-23363, Periodic Reporting](https://policyrisk.com/federal-register/2026-23363)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-23351 (as of 2026-11-17).
